A Double Blind (3rd Party Open) Randomized, Placebo Controlled, Parallel Group Dose Escalation Study To Investigate The Safety, Toleration And Pharmacokinetics Of Multiple Oral Doses Of Pf-04895162 In Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 27 Mar 2013
At a glance
- Drugs PF 4895162 (Primary)
- Indications Epilepsy
- Focus Pharmacokinetics
- 01 Mar 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 13 Nov 2012 Planned initiation date changed from 1 Oct 2012 to 1 Nov 2012 as reported by ClinicalTrials.gov.
- 01 Oct 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.